A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT01442532
A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT01436188
A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01427699
- Locations
- 🇨🇭
University Hospital of Basel, Basel, Switzerland
A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT01400646
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01400503
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01389973
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01384630
- Locations
- 🇺🇸
West Kentucky Dermatology, Owensboro, Kentucky, United States
🇺🇸Westlake Dermatology, Austin, Texas, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of Doripenem in Infants Less Than 12 Weeks of Age
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT01381848
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01381900
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 297
- Registration Number
- NCT01381874
© Copyright 2024. All Rights Reserved by MedPath